| Name | Title | Contact Details |
|---|
Founded in 2009, Celmatix is a personalized medicine company focused on fertility and women’s health. Our technology-enabled products empower people, through better data, to dramatically improve their chances of conceiving.
PureTech is a science-driven healthcare company, seeking to solve some of today`s toughest health challenges through disruptive approaches. PureTech has a pipeline of 12 operating companies, seven of which are “growth stage” with external validation including strategic partnerships, outside funding, proof-of-concept or peer review in prestigious scientific journals. PureTech is problem-focused and solution-agnostic, looking beyond traditional disciplines and approaching healthcare problems from different perspectives. Focusing on areas of significant unmet medical need, PureTech evaluates more than 650 ideas per year, prioritizing, selecting and testing what it believes to be the most scientifically and commercially promising concepts to advance. PureTech’s leading team and board, along with an advisory network of more than 50 experts across multiple disciplines, gives PureTech access to potentially groundbreaking science and technological innovations.
QUATRx Pharmaceuticals Company is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ArQule, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Xcell Bio is a San Francisco-based life science company dedicated to bringing an innovative primary cell control solution to the immunotherapy market to support research, drug discovery, and cell manufacturing. Xcell`s mission is to democratize maintenance, expansion and control of any primary cell type through its bench-top primary cell control systems, reagent kits, software, and standardized protocols. The technology delivers simple control of primary cell types from blood or solid tissue, including a range of immune cells, stem cells, and tumor cells. This patient-centric technology offers a unique and proprietary capability to improve immunotherapy efficacy, safety, and persistence through more predictive and iterative therapy development and rapid, highly-controlled clinical cell manufacturing.